Skip to main content
OpenTrials
Completed

NCT Number: NCT02510677

Three-dimensional Assessment of Intraventricular Dyssynchrony Using Fast Dobutamine Gated SPECT

The prognosis of patients with heart failure has improved due to recent breakthrough in medical treatment and cardiac resynchronization devices. However, there is no paraclinical parameter to assess response to cardiac resynchronization therapy (CRT). This is a major issue since about a third of implanted patients will not be improved by CRT. CZT SPECT allows to perform myocardial perfusion imaging in less than 4 minutes and is able to study myocardial perfusion, viability, left ventricular function, but also ventricular asynchrony.

Using low-dose dobutamine gated SPECT and CZT camera, we aimed to assess left ventricular dyssynchrony in viable segments in patients with heart failure eligible for CRT.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de Médecine Nucléaire du CHU de Caen

Caen, 14000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with heart failure on optimal medical therapy and targeted for cardiac resynchronization therapy according to current recommendations;
  • Age over 18 years
  • Clinically stable (without hospitalization for heart failure in the last month)
  • Sinus rhythm
  • Social security insurance
  • Signed consent form

Exclusion criteria

  • Recent history (less than 21 days) of acute coronary syndrome or unstable angina;
  • Recent history (less than 1 month) of acute heart failure;
  • Right bundle branch block;
  • Irregular heart rate;
  • Double-chamber cardiac pacemaker
  • Patients previously implanted with a single-chamber cardioverter-defibrillator must have at least 99 percent of unstimulated QRS.
  • Countraindication to dobutamine therapy;
  • Valvular heart disease, congenital heart disease, hypertrophic cardiomyopathy;
  • Significant Ventricular arrhythmias;
  • Hypertension (upper than 160/100 mmHg);
  • Pregnant, breastfeeding or guardianship

Treatment and study plan

myocardial perfusion scintigraphy

Other

Primary outcomes

  1. measures of dyssynchrony parameters

    Time frame: baseline

    The primary endpoint is reproducible quantitative measures of dyssynchrony parameters between two successive acquisitions basal (entropy, bandwidth, standard deviation phase histogram).

Sponsors and collaborators

Lead sponsor

University Hospital, Caen

Other

Registry information

Acronym: FAST DOGS

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Jul 29, 2015
Registry last updated
Feb 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.